News on altimmune
WitrynaAltimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 10. GAITHERSBURG, Md., Nov. 03, 2024 (GLOBE NEWSWIRE) -- … Witryna21 mar 2024 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide (formerly ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of …
News on altimmune
Did you know?
Witryna11 kwi 2024 · All news about ALTIMMUNE, INC. 08:53a: Altimmune Completes Enrollment in Phase 2 Trial of HepTcell to Treat Chronic Hepatitis .. MT. ... Analyst Recommendations on ALTIMMUNE, INC. 03/22: Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From.. MT. 01/20: WitrynaView the latest Altimmune Inc. (ALT) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Witryna21 mar 2024 · A new obesity treatment being developed by Altimmune met goals for weight loss in a mid-stage clinical trial, but the data showed it doesn’t have a leg up … Witryna22 mar 2024 · Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to …
WitrynaGet the latest Altimmune Inc (ALT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …
WitrynaGet Altimmune Inc (ALT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
Witryna21 mar 2024 · A new obesity treatment being developed by Altimmune met goals for weight loss in a mid-stage clinical trial, but the data showed it doesn’t have a leg up on other popular drugs on the market ... citati o skoli i ucenjuWitryna13 kwi 2024 · About ALT. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity … citati o osmehu na engleskomWitryna21 mar 2024 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In … citati o putovanjuWitryna11 kwi 2024 · Altimmune, Inc. announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (CHB). With the achievement of this milestone, data readout is planned for the first quarter of 2024. The multicenter clinical trial, which is being conducted at 26 sites in … citati o prijateljstvu ivo andricWitryna2 dni temu · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. citati o putovanjimaWitryna21 mar 2024 · What Happened: In pre-market trading, the stock of the troubled regional bank plunged 21.58% to $18.06, according to Benzinga Pro data. The stock shed a whopping 32.80% on Friday despite private ... citati o sestrinskoj ljubaviWitryna11 kwi 2024 · GAITHERSBURG, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the Company), today announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (CHB). … citati o snegu i ljubavi